Advertisement · 728 × 90
#
Hashtag
#CONTACT02
Advertisement · 728 × 90
Vall d’Hebron Institute of Oncology
Vall d’Hebron Institute of Oncology
@vhio.bsky.social
9 months ago
Post image

🔴 Una nueva combinación de fármacos muestra beneficios en pacientes con cáncer de próstata metastático resistente.

🗞️ Los resultados del estudio #CONTACT02 han sido publicados en @thelancetoncol.bsky.social  👉 https://linke.to/CONTACT-02VHIO_CAST

1 0 0 0
Vall d’Hebron Institute of Oncology
Vall d’Hebron Institute of Oncology
@vhio.bsky.social
9 months ago
Post image

🔴 A new drug combination reduces the risk of progression and death by up to 35% in patients with metastatic castration-resistant prostate cancer. 

🗞️ #CONTACT02 trial results were published in @thelancetoncol.bsky.social 👉 https://linke.to/CONTACT02VHIO

0 0 0 0
OncoDaily
OncoDaily
@oncodaily.bsky.social
9 months ago
Preview
CONTACT-02 Trial 2025 Update: Atezolizumab Plus Cabozantinib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - OncoDaily CONTACT-02 trial showed that Atezolizumab plus Cabozantinib improves PFS in Metastatic Castration-Resistant Prostate Cancer (mCRPC).

CONTACT-02 Trial 2025 Update: Atezolizumab Plus Cabozantinib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CONTACT02 #Atezolizumab #Cabozantinib #ProstateCancer #mCRPC

4 1 0 0